Mineralys Therapeutics (MLYS) Expected to Announce Quarterly Earnings on Thursday

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($1.02) per share for the quarter.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.00) by $0.02. On average, analysts expect Mineralys Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Mineralys Therapeutics Stock Down 4.9 %

Shares of MLYS traded down $0.77 during trading hours on Tuesday, reaching $14.87. 150,052 shares of the company traded hands, compared to its average volume of 439,528. The business has a fifty day moving average price of $13.55 and a 200-day moving average price of $12.38. Mineralys Therapeutics has a 12-month low of $8.24 and a 12-month high of $18.38. The stock has a market capitalization of $964.38 million, a P/E ratio of -4.10 and a beta of -0.30.

Wall Street Analyst Weigh In

MLYS has been the topic of several research analyst reports. The Goldman Sachs Group dropped their price target on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. HC Wainwright raised their price target on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a "buy" rating in a research report on Wednesday, April 2nd. Finally, Guggenheim restated a "buy" rating on shares of Mineralys Therapeutics in a research note on Monday, February 24th.

Insiders Place Their Bets

In related news, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.06, for a total transaction of $129,729.42. Following the completion of the transaction, the chief financial officer now directly owns 215,340 shares in the company, valued at approximately $2,597,000.40. This trade represents a 4.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jon Congleton sold 15,319 shares of the firm's stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $12.19, for a total transaction of $186,738.61. Following the sale, the chief executive officer now directly owns 862,289 shares in the company, valued at $10,511,302.91. The trade was a 1.75 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 93,213 shares of company stock valued at $1,360,567. Company insiders own 33.24% of the company's stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.